Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2015

View Archived Issues

Novel NCSTN mutation may underlie familial hidradenitis suppurativa

Caspase-1 as a new target to prevent diabetic retinopathy

Daiichi Sankyo presents first-in-human results for DS-1040

First subject dosed in first-in-human study of ABX-1431

Summit Therapeutics' SMT-19969 receives FDA fast track designation

Novo Nordisk discontinues GLP-1 patch collaboration with Zosano

Manremyc signs Indian agreement for sale of food supplement to curb TB

Pfizer announces immunological disease collaboration

Roche and Genentech patent TYK2 kinase inhibitors

Actelion divulges new antibacterials

Gruenenthal reports development of CRAC inhibitors

Bayer Schering Pharma presents glucose transport inhibitors

Almirall reports JAK inhibitors

Merck Patent describes PDHK2 inhibitors

FDA accepts IND for trial using Viaskin Milk in milk-induced eosinophilic esophagitis

Oramed signs letter of intent for Chinese investment and licensing deal

Depomed board rejects acquisition proposal from Horizon Pharma

Tillotts acquires ex-U.S. rights to Entocort

Sernova receives funding for Cell Pouch type 1 diabetes collaboration

City of Hope launches clinical trial of immune suppression strategy in islet transplantation

Wayne State University receives grant to repurpose rosiglitazone for pre-eclampsia

Novartis starts phase II/III trial of PI3Kdelta inhibitor

Micell's sirolimus-eluting stent enters phase III trial in coronary heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...